|
English
|
正體中文
|
简体中文
|
Total items :0
|
|
Visitors :
52684918
Online Users :
766
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
|
|
|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"_"
Showing items 76-85 of 4992 (500 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12 |
DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN
|
Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh |
| 國立成功大學 |
2024-12 |
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
|
Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A. |
Showing items 76-85 of 4992 (500 Page(s) Totally)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
View [10|25|50] records per page
|
